NEW YORK March 14 - Silico Insights is collaborating with Ashni Naturaceuticals to identify regulatory and post-translational pathways from genomics and proteomics data, the companies said Wednesday.
Under the terms of the partnership, Silico Insights of Woburn, Mass., will apply its iSight bio informatics platform to establish dependencies and pathways from research data generated by Ashni.
Ashni of Salt Lake City, Utah, will use its genomic BioPrinting technology to characterize anti-inflammatory action of mixtures of natural compounds.
Nandan Padukone, president of Silico Insights, said that the two companies have filed a joint patent application on the pathway identification methodology, which combines Silico Insights’ bioinformatics platform and Ashni’s proteomics knowledge.
Financial terms of the agreement were not disclosed.
Ashni intends to build compound libraries by combining genomic and proteomic research with the study of natural compounds.
"The ability to rapidly identify genetic pathways and the means to regulate them using various natural compounds promise new ways to discover treatments for pain," said John Babish, executive vice president of research at Ashni. "Integrating state-of-the-art informatics techniques from Silico Insights helps us decipher the complex data into meaningful high-value information with speed and accuracy.”
The two companies are still working out the details how they intend to distribute the resulting data. “We haven’t finalized what the final product will be,” Padukone said.
Padukone said that Silico Insights has been approached by a number of post-genomic tool and data providers interested in using the company’s technology to analyze complex data.